Formulation & process development · MelbourneInvestor information ↗

RESEARCH & VALIDATION

Evidence with
its context intact.

The important question is not just whether a result exists. It is what was tested, how it was measured and what the result can establish.

InternalLab-scale development reported
IndependentFormulation assessment next
Scale-upPilot repeatability gate
ProductReadiness, per formulation

CURRENT DEVELOPMENT BASIS

Internal work informs the next questions.

The supplied company materials describe internal lab-scale formulation and process testing. This website does not present that work as completed clinical validation or repeatable commercial manufacture.

Full supporting protocols and raw data are not published here. Request the current status and the approved material available for review.

DISTINCT EVIDENCE TYPES

Four questions. Different evidence.

Manufacturing process

Defined batch conditions, repeatability and measured resource use. These findings do not establish a skin benefit.

Formulation performance

Active integrity, rheology, stability, microbiology and packaging compatibility, as appropriate to the formulation.

Finished-product outcomes

Relevant assessment of the exact formula, intended use and advertised outcome.

Background research

Published work using other formulations or materials, attributed as context rather than OPP proof.

DEVELOPMENT MILESTONES

A sequence of evidence gates.

Work reported to date

Internal lab-scale development

Integrated formulation and process work described in company materials; not an independently verified performance claim.

Further validation

Independent formulation assessment

Define the test article, method, comparator, endpoints and limitations before publishing results.

Scale-up gate

Pilot-scale repeatability

Establish documented batch scale, acceptance criteria and consistency across relevant runs.

Product-specific gate

Product & packaging readiness

Complete the relevant safety, stability, microbiology, compatibility and claim-support requirements.

Future gate

Commercial manufacture & launch

Establish repeatable production and release arrangements before individual products enter supply.

Parallel workstream

Intellectual-property development

Keep patent status, confidentiality and technical disclosure under appropriate review.

R&D PROGRAMME

What we are working on.

GlowSense R&D activities are registered under the Australian Government R&D Tax Incentive programme, as reported by the company. Status below is company-reported and is not independent verification.

Complete

Provisional patent application

Australian provisional applications relating to OPP have been filed, as reported by the company. A provisional filing does not grant patent rights.

Complete

Preliminary spicule characterisation

Preliminary bench work on spicule sizing, purity and morphology, reported internally.

Active

Batch documentation

Batch manufacturing records being developed for trial formulations, in line with GMP documentation practice.

Active

Formulation finalisation

Formulation dossiers, stability testing protocols and CoA frameworks in development for selected formulations.

Planned

Analytical stability validation

Quantitative analytical testing of active stability before and after OPP co-formulation.

Planned

Cream and moisturiser formats

Extending the OPP approach beyond gel and serum formats, assessed for each new format.

Planned

International patent filing

International filing under the PCT route, as part of the intellectual-property workstream.

Planned work is not a completed result, and target dates are not commitments. Contact GlowSense for current status.

BACKGROUND RESEARCH

Useful context is not product proof.

A 2017 study investigated Haliclona spicules with model dextrans using laboratory and animal models. It did not test GlowSense OPP or a PERVIA serum.

It can inform research questions, but it does not substantiate a PERVIA-specific PDRN delivery, human safety or clinical benefit claim.

Zhang et al., Molecular Pharmaceutics (2017)https://pubmed.ncbi.nlm.nih.gov/28763230/

PUBLISHED LITERATURE

Background reading.

Published work on spicule-based delivery that informs our research questions. None of these studies tested GlowSense OPP or a PERVIA product.

Molecular Pharmaceutics · 2017

Skin delivery of hydrophilic biomacromolecules using marine sponge spicules

Zhang et al. Laboratory and animal models using model dextrans. Did not test GlowSense OPP or a PERVIA serum.

View source

Pharmaceutics (MDPI) · 2021

Spicule-based topical delivery of therapeutic peptides

Compares several marine sponge spicule species using a model peptide in laboratory settings. Background context only.

View source

PMC · 2025

Nano-encapsulated spicule system with MSC secretome

Single-arm study of a different spicule-based system and ingredient. It does not establish OPP or PERVIA outcomes.

View source

OUR PUBLICATION STANDARD

No borrowed performance claims.

We do not apply a published penetration multiple to an untested OPP product, present a planned study as complete or imply that a laboratory result establishes a clinical outcome.

Numerical retention and resource-saving claims remain outside this public copy until their methods, scope and evidence have been reviewed.

Let’s talk about the next step.

Technology, evidence and business enquiries.

Contact GlowSense